Navigation Links
ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
Date:3/24/2009

EXTON, Pa., March 24 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) announced it has repurchased, in a privately negotiated transaction, $45 million principal amount or 18 percent of the company's Senior Convertible Notes due March 2017 for total consideration of approximately $21.2 million. Following these repurchases, senior convertible notes representing $205 million of principal debt are outstanding.

As a result of the convertible note repurchase, ViroPharma expects that its fully diluted shares outstanding will be decreased by approximately 2.38 million shares. The company is finalizing the accounting for the resulting net pre-tax gain in accordance with the company's adoption of FASB Staff Position (FSP) No. APB 14-1, Accounting for Convertible Debt Instruments That May Be Settled in Cash upon Conversion (Including Partial Cash Settlement). This gain will be reported in the financial statements for the first quarter of 2009. ViroPharma anticipates that the taxable gain arising from the repurchase will qualify for deferral until 2014 in accordance with the provisions of the American Recovery and Reinvestment Act of 2009. The senior convertible note repurchase will reduce the company's interest expense for the balance of fiscal 2009 by approximately $1.6 million. Additionally, the corresponding hedge and warrant (call spread) entered into by ViroPharma in March 2007 was unwound for the bonds repurchased. ViroPharma anticipates that the annual cash savings as a result of this repurchase will be approximately $0.9 million per year.

"A dislocation in the capital markets has allowed us to repurchase some of our outstanding debt at an attractive discount to the principal amount of the notes and reduce our fully diluted shares outstanding," commented Charles Rowland, ViroPharma's vice president and chief financial o
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
2. ViroPharma to Present at Three November Healthcare Conferences
3. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
4. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
5. ViroPharma to Present at Three October Healthcare Conferences
6. ViroPharma to Present at Three September Healthcare Conferences
7. ViroPharma To Acquire Lev Pharmaceuticals
8. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
9. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
10. ViroPharma to Present at Two Upcoming Healthcare Conferences
11. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... plc (NYSE: ACT ) today confirmed that a ... Second Circuit has issued a ruling upholding a December ... distribution of NAMENDA ® (memantine HCl) immediate-release tablets. ... "While we are disappointed by the Court,s decision ... strong efforts to convey the significant benefits of NAMENDA ...
(Date:5/22/2015)... NJ (PRWEB) May 22, 2015 ... new white paper that explores the potential of big ... The white paper was developed to help life sciences ... can leverage data to gain critical business insights. , ... large amounts of data driven by patient profiling, compliance ...
(Date:5/21/2015)... St. Louis, MO (PRWEB) May 21, 2015 ... that assesses the safety and efficacy of pharmaceutical products ... Access Drive Maryland Heights, MO 63043, a 50,000 sq. ... their current location, to enable strategic growth. Facility renovations ... offices to the new space will occur in September. ...
(Date:5/21/2015)... 2015  Prima Biomed Ltd. (NASDAQ: PBMD ) ... become a leader in the development of immunotherapeutic products ... final CVac data from the Phase II CAN-003 ovarian ... a clinically meaningful improvement in Overall Survival ("OS") over ... In the group of second remission patients (n=20), ...
Breaking Biology Technology:Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 2Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 3Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 4Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 5Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 6Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 7Actavis Confirms Appeals Court Ruling Requiring Continued Distribution of NAMENDA IR 8New White Paper Explores the Potential of Big Data Analytics in Life Sciences and Healthcare 2Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 2Seventh Wave Laboratories Purchases Building for Expansion, Upcoming Move 3Correction Continues after Big Move - BrokerBank Securities, Inc. 2
... March 27, 2012 Vermillion, Inc. (NASDAQ: ... and operational results for the fourth quarter and full ... Full Year 2011 Operational Highlights In ... diagnostic designed to help differentiate benign from malignant ovarian ...
... March 26, 2012 The L,ORÉAL-UNESCO For Women in ... a week of scientific meetings and debates. , ... International Fellows will be presenting their research at the Pasteur Institute ... at the Institute where the International Fellows can be met individually ...
... massive particles has intrigued physicists for more than 80 years, ... behaviour in conflict with our everyday ideas of what ... now succeeded in shooting a movie which shows the build-up ... is so large (up to 0.1 mm) that you can ...
Cached Biology Technology:Vermillion Reports Fourth Quarter and Full Year 2011 Results 2Vermillion Reports Fourth Quarter and Full Year 2011 Results 3Vermillion Reports Fourth Quarter and Full Year 2011 Results 4Vermillion Reports Fourth Quarter and Full Year 2011 Results 5Vermillion Reports Fourth Quarter and Full Year 2011 Results 6Vermillion Reports Fourth Quarter and Full Year 2011 Results 7Vermillion Reports Fourth Quarter and Full Year 2011 Results 8The 14th Annual L'Oréal-Unesco Awards or Women on Science: From March 26 to March 29, Paris Welcomes and Honours Tomorrow's Scientific Talents 2The 14th Annual L'Oréal-Unesco Awards or Women on Science: From March 26 to March 29, Paris Welcomes and Honours Tomorrow's Scientific Talents 3The 14th Annual L'Oréal-Unesco Awards or Women on Science: From March 26 to March 29, Paris Welcomes and Honours Tomorrow's Scientific Talents 4Single molecules in a quantum movie 2
(Date:4/14/2015)... April 14, 2015  HYPR Corp. today announced ... ® ) Alliance tm , an industry consortium ... commit to share technology and collaborate to deliver ... interoperable, more secure and private, and easier to ... verification that protects sensitive user information and eliminates ...
(Date:4/13/2015)... , April 13, 2015 ... Research, "Global Biometrics Market Forecast & Opportunities, 2020", the ... CAGR of around 14% till 2020. The biometrics ... large scale implementation and review of biometric management ... of new products with greater efficiency, are resulting ...
(Date:4/10/2015)... Research and Markets ( http://www.researchandmarkets.com/research/cjk4gb/security ... Competitive Profiles - NEC" report to their offering. ... will continue to supply a range of IT security ... company focus on the development of a Big Data ... in the Asia-Pacific region is ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2
... believes his latest work moves scientists closer to a cure ... genetic diseases. , The Journal of Biological Chemistry ... the School of Medicine,s Department of Medical Pharmacology and Physiology ... recognized as the "paper of the week" for the journal, ...
... In an expansion of its ongoing effort to promote ... York Stem Cell Foundation (NYSCF) today named the first ... Investigators will receive up to $1.5 million over the ... other scientists and foster innovative high-risk/high reward research to ...
... Calif., Oct. 12 Stayhealthy, Inc. an innovative, ... fitness measurement, announced that it will join Hooper ... wellness, prevention and chronic care management October 13-15 ... healthcare decision makers. Earlier this year, Stayhealthy announced ...
Cached Biology News:1 step closer to a drug treatment for cystic fibrosis, MU professor says 2NYSCF announces 2010 NYSCF Investigators 2NYSCF announces 2010 NYSCF Investigators 3NYSCF announces 2010 NYSCF Investigators 4NYSCF announces 2010 NYSCF Investigators 5Stayhealthy® Joins Hooper Holmes to Provide Complimentary Web-Based Biometric Screenings to All Participants at Care Continuum Alliance Conference 2Stayhealthy® Joins Hooper Holmes to Provide Complimentary Web-Based Biometric Screenings to All Participants at Care Continuum Alliance Conference 3Stayhealthy® Joins Hooper Holmes to Provide Complimentary Web-Based Biometric Screenings to All Participants at Care Continuum Alliance Conference 4
Sheep polyclonal to Malate Dehydrogenase ( Abpromise for all tested applications). Antigen: Full length protein - Pig heart malate dehydrogenase. Entrez Gene ID: 4190 Swiss Protein ID: P...
...
... The epitope specific for Nabeta2 ... other known proteins.,SPECIES REACTIVITIES: ... on human because the immunogen ... residues). Reactivity with other species ...
Chicken polyclonal to HAGH ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to N terminal amino acids 110-260 of Human HAGH. Entrez GeneID: 3029 Swiss ...
Biology Products: